Tomorrow Options announces name change and launches in the US
This new step in the company’s internationalisation strategy coincides with a new funding cycle worth 2.6 million dollars (1.91 million Euros) from venture capital funds managed by Portugal Ventures. This investment complements a 2.4 million dollar (1.767 million Euros) investment by Portugal Ventures in 2008.
The new funding enables Kinematix to accelerate sales and marketing activities worldwide, in order to fuel continued market growth of its proven products. Kinematix’s products incorporate the latest in micro-electronic sensing, with connected health features designed for customisation, efficiency and enhanced communications. Both of its healthcare products have received US Food and Drug Administration (FDA) and CE Mark clearance.
Paulo Ferreira dos Santos, CEO at Kinematix, explains the name change. "The Kinematix name better reflects our dedication to monitoring body dynamics during real-life activities. We are focused on markets where feedback on body dynamics and lack of connectivity are complicating positive outcomes, patient or customer care, and efficiency.”
OJE, 29 November 2013
